Abstract 2135P
Background
G8 and GA assessments to screen for frailty and facilitate appropriate interventions have been recommended by the International Society for Geriatric Oncology in older adults with cancer. The main objective of this study is to evaluate the impact of G8 and GA-based interventions on the QoL of older Asian adults with cancer.
Methods
This is a prospective study of cancer patients aged ≥70 treated at the National University Cancer Institute, Singapore. The G8, CGA, and EORTC QLQ 30 questionnaires were administered at study entry. Targeted interventions were offered by the multi-disciplinary geriatric oncology (GO) service. After three months, a follow-up EORTC QLQ 30 was repeated for those who required geriatric interventions. Primary outcome measure was comparison of pre/post- EORTC QLQ 30 scores.
Results
N=230 patients were accrued. Median age was 74 (range:70-90). Majority were male (56%), diagnosed with gastrointestinal cancers (35%) and receiving palliative intent treatment (60%). Based on GA, 11% were classified as frail, 58% as pre-frail and 31% as fit. 79% had G8 scores ≤14. Pre-frail, frail and those with G8 ≤14 had lower baseline EORTC QOL function scores and higher EORTC QOL symptom scores (p<0.05). They also had significantly shorter overall survival (OS) compared to fit or with patients G8>14. (HR=2.54 95% CI 1.46-4.43, p=0.001 for frail vs fit patients; HR=1.72 95% CI 1.18-2.53, p=0.005 for pre-frail vs fit patients; HR=1.51 95% CI 1.05-2.18, p=0.027 for G8 ≤14 vs >14). GO interventions were suggested for 144 patients with 104 patients completing a 2nd EORTC QOL questionnaire. These patients reported significant improvements in the EORTC emotional and social functioning domains (mean difference +4.6, p<0.001 and +12.3 p<0.001, respectively), a significant reduction in the EORTC symptom scale of pain, insomnia, constipation, and financial difficulties (mean difference -5.8 p=0.003, -8.3 p<0.001, -9.0 p<0.001, and -6 p=0.01), with no significant deterioration in other QOL domains.
Conclusions
Geriatric assessment-based targeted interventions delivered by a multidisciplinary GO service significantly improved multiple QOL domains in older Asian adults undergoing cancer treatment.
Clinical trial identification
DSRB Study Reference Number: 2017/00214.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Singapore Cancer Society.
Disclosure
C.E. Chee: Financial Interests, Institutional, Advisory Board: Merck, AstraZeneca, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
2204P - Clinical predictors and inflammatory markers for malignant pleural mesothelioma prognosis: A retrospective study in a Spanish Medical Oncology Unit
Presenter: Mora Guardamagna
Session: Poster session 07
2205P - Tumor-infiltrating lymphocytes score possesses a relation with adjuvant chemo-immunotherapy benefit and cellular morphology in large-cell neuroendocrine carcinoma
Presenter: Zhiwen Luo
Session: Poster session 07
2207P - Mainstream germline genetic testing in routine oncological care of EGFR mutant non-small cell lung cancer in the United Kingdom
Presenter: Hazel O'Sullivan
Session: Poster session 07
2208P - The single-cell proteomic landscape of pulmonary lymphoepithelioma-like carcinoma
Presenter: Chi Cho
Session: Poster session 07
2209P - Mutational status of non-small cell lung cancer in Portugal: A multicentric study
Presenter: Joana Duarte
Session: Poster session 07
2210P - Reprogramming of pyrimidine metabolism drives tumorigenesis in NF2-deficient malignant pleural mesothelioma
Presenter: Duo Xu
Session: Poster session 07
2234P - Local immune-related adverse events (irAEs) are more common in tumor-bearing organs
Presenter: Steve Blum
Session: Poster session 07
2235P - Chemotherapy priming leads to hypermutability and immune surveillance in colorectal cancer
Presenter: Pietro Paolo Vitiello
Session: Poster session 07
2236P - MHC-II neoantigens and copy number alterations (CNA) drive immune checkpoint inhibitor (ICI) response in metastatic melanoma (MM)
Presenter: Benjamin Shum
Session: Poster session 07